CN114280312A - Whole blood separation membrane for immunofluorescence chromatography detection and preparation method and application thereof - Google Patents
Whole blood separation membrane for immunofluorescence chromatography detection and preparation method and application thereof Download PDFInfo
- Publication number
- CN114280312A CN114280312A CN202011030495.4A CN202011030495A CN114280312A CN 114280312 A CN114280312 A CN 114280312A CN 202011030495 A CN202011030495 A CN 202011030495A CN 114280312 A CN114280312 A CN 114280312A
- Authority
- CN
- China
- Prior art keywords
- whole blood
- separation membrane
- reagent
- conjugate
- blood separation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention provides a whole blood separation membrane for immunofluorescence chromatography detection and a preparation method and application thereof, belonging to the technical field of biological sample treatment, wherein the whole blood separation membrane for immunofluorescence chromatography detection takes a glass fiber membrane as a base material, and a conjugate with antigen specificity, a sealing reagent, a conjugate release reagent and a hydrophilic reagent are fixed on the glass fiber membrane; the antigen-specific conjugate consists of a polyclonal antibody specifically binding to a target detection substance, immunoglobulin G, and a microparticle having a fluorescent label. The whole blood separation membrane provided by the invention has stable characteristics and high red blood cell separation efficiency, can remove the influence of interference substances, increases the specific binding of immunity, and ensures the accuracy and repeatability of detection results.
Description
Technical Field
The invention belongs to the technical field of biological sample treatment, and particularly relates to a whole blood separation membrane for immunofluorescence chromatography detection, and a preparation method and application thereof.
Background
The rapid diagnostic reagent based on the lateral chromatography immunofluorescence detection principle can be directly used for whole blood analysis, but the current technology generally needs whole blood pretreatment, such as centrifugal extraction of plasma, or addition of buffer for dilution or reaction, and the like.
If the untreated glass fiber membrane is directly used for red blood cell separation, endogenous interfering substances, sample viscosity or hydrophilic characteristics and the like can have great influence on the sensitivity, specificity and accuracy of antibody combination reaction on a downstream reaction membrane, so that the judgment of a result is influenced.
Disclosure of Invention
In view of the above, the present invention aims to provide a whole blood separation membrane for immunofluorescence chromatography detection, and a preparation method and applications thereof; the whole blood separation membrane has stable characteristics and high red blood cell separation efficiency, can remove the influence of interference substances, increases the specific binding of immunity, and ensures the accuracy and repeatability of detection results.
In order to achieve the above purpose, the invention provides the following technical scheme:
the invention provides a whole blood separation membrane for immunofluorescence chromatography detection, which takes a glass fiber membrane as a base material, wherein an antigen-specific conjugate, a blocking reagent, a conjugate release reagent and a hydrophilic reagent are fixed on the glass fiber membrane;
the antigen-specific conjugate is composed of a polyclonal antibody specifically bound with a target detection object, immunoglobulin G and microparticles with fluorescent markers;
the conjugate is positioned at the top of the whole blood separation membrane and is 0.5-5 mm away from the top edge of the whole blood separation membrane;
the hydrophilic reagent is positioned at the bottom of the whole blood separation membrane and is 0.5-5 mm away from the bottom edge of the whole blood separation membrane;
the position of the conjugate releasing agent coincides with the position of the conjugate.
Preferably, the sealing reagent is positioned in the middle of the whole blood separation membrane and is 10-20 mm away from the top edge of the whole blood separation membrane.
Preferably, the blocking reagent comprises a first surfactant, a first blocking solution, a first buffer, sodium chloride and a first preservative; the first surfactant comprises one or more of PVP10, S10G and Tween 20; the first sealing solution comprises one or more of a casein sodium salt solution, a bovine serum albumin solution and a heterogeneous sealing reagent HBR; the first preservative comprises ProClin300 or ProClin 950; the pH value of the sealing reagent is 7-9; the blocking reagent was dispensed in a volume of 10. mu.L/cm to full membrane saturation.
Preferably, the conjugate release agent comprises a second surfactant, a second blocking solution, a second buffer, sodium chloride, and a second preservative; the second surfactant comprises PVP10 or S10G; the second sealing solution comprises a sodium caseinate solution; the second buffer comprises Tris; the second preservative ProClin300 or ProClin 950; the pH value of the conjugate release reagent is 7-9; the distribution volume of the conjugate release reagent is 10-50 muL/cm.
Preferably, the hydrophilic agent comprises a third surfactant, a third buffer and a third preservative; the third surfactant is S10G; the third buffer solution is 20 mM-100mM Tris; the third corrosion inhibitor is ProClin300 or ProClin 950; the pH value of the hydrophilic reagent is 6.5-8.5; the distribution volume of the hydrophilic reagent is 10-50 mu L/cm.
Preferably, the concentration of the first buffer solution and the second buffer solution is 30-100 mM independently.
The invention provides a preparation method of the whole blood separation membrane, which comprises the following steps:
1) mixing and incubating a polyclonal antibody specifically bound with a target detection object, immunoglobulin G, a buffer solution and microparticles with fluorescent labels for 15-60 min to obtain a conjugate solution;
2) mixing and coupling the conjugate solution, the sealing solution and the EDAC solution for 1-3 h to obtain an antigen-specific conjugate;
3) and fixing the antigen-specific conjugate, the blocking reagent, the conjugate releasing reagent and the hydrophilic reagent on a glass fiber membrane, and drying to obtain the whole blood separation membrane.
Preferably, the drying in the step 3) is vacuum drying, and the vacuum degree of the vacuum drying is 3-15 Torr; and the vacuum drying time is 2-4 h.
The invention provides application of the whole blood separation membrane in preparation of a lateral chromatography immunofluorescence detection test strip.
Preferably, the whole blood separation membrane is used as a sample pad of a test strip.
The invention has the beneficial effects that: the whole blood separation membrane provided by the invention takes a glass fiber membrane as a base material, and a conjugate with antigen specificity, a blocking reagent, a conjugate release reagent and a hydrophilic reagent are fixed on the glass fiber membrane; can realize direct processing or analysis of biological samples (such as whole blood collected from a patient), does not need sample pretreatment such as sample dilution and the like, simplifies the sample processing flow of rapid diagnosis, and improves the accuracy and repeatability of detection results.
The glass fiber membrane can directly filter red blood cells, so that blood particles or cell components in a blood sample are retained on the separation membrane, the blood sample has high diffusion speed and low protein adsorption rate; wherein the conjugate with antigen specificity is combined with a biomarker to be detected and is subjected to fluorescent labeling, so that the conjugate is smoothly released to a downstream reaction membrane and is detected; the sealing reagent is used for sealing endogenous interfering substances and heterogeneous interfering substances, changing the viscosity or hydrophilic property of a sample and the like; the function of the conjugate releasing agent is to smoothly release the conjugate with antigen specificity on the separation membrane; the hydrophilic reagent can improve the hydrophilicity of the separation membrane, shorten the absorption time of the whole blood sample on the separation membrane and improve the detection efficiency; the conjugate is added on the smooth surface of the glass fiber, so that the contact surface of the conjugate and a downstream reaction film is increased; the ability of conjugate conjugates to reside on the membrane surface and be released to downstream reaction membranes can be significantly increased.
In conclusion, the whole blood separation membrane provided by the invention has stable characteristics and high red blood cell separation efficiency, can remove the influence of interfering substances, increases the specific binding of immunity, and ensures the accuracy and repeatability of detection results.
Drawings
FIG. 1 is a schematic structural view of a whole blood separation membrane according to the present invention.
Detailed Description
The invention provides a whole blood separation membrane for immunofluorescence chromatography detection, which takes a glass fiber membrane as a base material, wherein an antigen-specific conjugate, a blocking reagent, a conjugate release reagent and a hydrophilic reagent are fixed on the glass fiber membrane; the antigen-specific conjugate consists of a polyclonal antibody specifically binding to a target detection substance, immunoglobulin G, and a microparticle having a fluorescent label.
In the present invention, the glass fiber membrane is preferably an RB1.1 glass fiber membrane; the RB1.1 glass fiber membrane is preferably available from RB company. In the invention, the glass fiber membrane can directly filter red blood cells, so that blood particles or cell components in a blood sample are retained on the separation membrane, and the blood sample on the glass fiber membrane has high diffusion speed and low protein adsorption rate.
In the present invention, the antigen-specific conjugate is composed of a polyclonal antibody specifically binding to a target detection substance, immunoglobulin G, and a microparticle having a fluorescent label. In the present invention, the mass ratio of the polyclonal antibody, immunoglobulin G and the microparticles having a fluorescent label is different according to the product, and in one embodiment of the present invention, the mass ratio of the polyclonal antibody, immunoglobulin G and the microparticles having a fluorescent label is 25:5: 1. The source of the polyclonal antibody is not particularly limited in the present invention, and the polyclonal antibody can be prepared by a conventional method for preparing a polyclonal antibody in the art. In the present invention, the immunoglobulin G is used as a standard reference substance, and the immunoglobulin G can be selected from rabbit IgG. In the present invention, the microparticle having a fluorescent marker is preferably G1 (manufactured by Life Technologies; Cat. No. 93470720010250). In the invention, the conjugate is positioned on the top of the whole blood separation membrane and is 0.5-5 mm away from the top edge of the whole blood separation membrane. In the present invention, the volume of the conjugate is preferably 2 to 10. mu.L.
In the invention, the sealing reagent is positioned in the middle of the whole blood separation membrane and is 10-20 mm away from the top edge of the whole blood separation membrane. In the present invention, the distribution volume of the blocking reagent is preferably 10. mu.L/cm to the whole membrane permeation. In the present invention, the blocking reagent preferably includes a first surfactant, a first blocking solution, a first buffer, sodium chloride, and a first preservative; the first surfactant preferably comprises one or more of PVP10, S10G and Tween 20; in the invention, the concentration of PVP10 is preferably 1-5%, and the concentration of S10G is preferably 0.2-2%; the concentration of the Tween 20 is preferably 0.05-0.5%. In the invention, the first blocking solution comprises one or more of a casein sodium salt solution, a bovine serum albumin solution and a heterogeneous blocking reagent HBR; in the present invention, the concentration of the sodium caseinate solution is preferably 0.2% to 5%, and the concentration of the bovine serum albumin solution is preferably 1% to 8%.
In the present invention, the first buffer is preferably 30mM-100mM Tris.
In the present invention, the first preservative preferably comprises ProClin300 or ProClin 950; the concentration of ProClin300 is preferably 0.02-0.1%, and the concentration of ProClin950 is preferably 0.02-0.1%.
In the present invention, the concentration of sodium chloride is preferably 50 to 500 mM. In the invention, the pH value of the blocking reagent is preferably 7-9.
In the present invention, the position of the conjugate releasing agent coincides with the position of the conjugate; the distribution volume of the conjugate releasing agent is preferably 10 to 50. mu.L/cm. In the present invention, the conjugate-releasing agent preferably comprises a second surfactant, a second blocking solution, a second buffer, sodium chloride and a second preservative; in the present invention, the second surfactant preferably includes PVP10 or S10G; in the invention, the concentration of PVP10 is preferably 1-5%, and the concentration of S10G is preferably 0.2-2%; in the invention, the second sealing solution comprises a sodium caseinate solution, and the concentration of the sodium caseinate solution is preferably 0.2-5%; the second buffer comprises Tris, the concentration of the Tris is preferably 30mM-100 mM; the second preservative ProClin300 or ProClin 950; the concentration of ProClin300 is preferably 0.02-0.1%, and the concentration of ProClin950 is preferably 0.02-0.1%. In the present invention, the pH of the conjugate releasing agent is preferably 7 to 9.
In the invention, the hydrophilic reagent is positioned at the bottom of the whole blood separation membrane and is 0.5-5 mm away from the bottom edge of the whole blood separation membrane; the distribution volume of the hydrophilic reagent is preferably 10-50 mu L/cm. In the present invention, the hydrophilic agent includes a third surfactant, a third buffer, and a third preservative. In the invention, the third surfactant is S10G, and the concentration of the S10G is preferably 0.2-2%; the third buffer solution is preferably 20 mM-100mM Tris; the third corrosion inhibitor is ProClin300 or ProClin 950; the concentration of ProClin300 is preferably 0.02-0.1%, and the concentration of ProClin950 is preferably 0.02-0.1%. In the invention, the pH value of the hydrophilic reagent is 6.5-8.5. In the present invention, the concentrations of the above reagents are all mass percentage concentration.
The invention also provides a preparation method of the whole blood separation membrane, which comprises the following steps: 1) mixing and incubating a polyclonal antibody specifically bound with a target detection object, immunoglobulin G, a buffer solution and microparticles with fluorescent labels for 15-60 min to obtain a conjugate solution; 2) mixing and coupling the conjugate solution, the sealing solution and the EDAC solution for 1-3 h to obtain an antigen-specific conjugate; 3) and fixing the antigen-specific conjugate, the blocking reagent, the conjugate releasing reagent and the hydrophilic reagent on a glass fiber membrane, and drying to obtain the whole blood separation membrane.
In the invention, a polyclonal antibody specifically bound with a target detection object, immunoglobulin G, a buffer solution and microparticles with fluorescent labels are mixed and incubated for 15-60 min to obtain a conjugate solution. The present invention is not particularly limited with respect to the proportions of the polyclonal antibody, immunoglobulin G, buffer solution and microparticles having a fluorescent label; in a specific embodiment of the present invention, the mass ratio of the polyclonal antibody, immunoglobulin G and the microparticles with fluorescent labels is 25:5: 1. In the practice of the present invention, the polyclonal antibody and immunoglobulin G are preferably diluted with a buffer solution and then mixed with the fluorescent-labeled microparticles. In the present invention, the buffer solution is preferably 20mM 2- (N-morpholino) ethanesulfonic acid; in the invention, the temperature of the mixed incubation is preferably 10-30 ℃, and the time of the mixed incubation is preferably 20-55 min.
After the conjugate solution is obtained, the conjugate solution, the blocking solution and the EDAC solution are mixed and coupled for 1-3 h to obtain the conjugate with antigen specificity. In the present invention, the blocking solution is preferably a 1% bovine serum albumin solution; in the invention, the EDAC solution is preferably obtained by mixing EDAC and MES buffer solution, wherein the concentration of EDAC is preferably 1-20 mg/mL, and the concentration of MES is preferably 5-50 mM. After the conjugation, the conjugated conjugate is preferably obtained by mixing the reaction solution after the conjugation with an MES solution containing 0.3% bovine serum albumin, and removing unbound antibodies or other chemicals by centrifugation or liquid exchange.
After the conjugate is obtained, the antigen-specific conjugate, the blocking reagent, the conjugate releasing reagent and the hydrophilic reagent are directly distributed on a glass fiber membrane through a catheter, and the whole blood separation membrane is obtained by drying. In the present invention, the order of the fixed distribution of the conjugate, the blocking reagent, the conjugate releasing reagent and the hydrophilic reagent is not particularly limited, but the blocking reagent, the conjugate releasing reagent and the hydrophilic reagent are preferably distributed simultaneously on the glass fiber membrane, and the conjugate is redistributed on the glass fiber membrane after the distribution of the three reagents is completed and dried. In the invention, the drying is preferably vacuum drying, and the vacuum degree of the vacuum drying is preferably 3-15 Torr; the vacuum drying time is preferably 2-4 h.
The invention also provides application of the whole blood separation membrane in preparation of a lateral chromatography immunofluorescence detection test strip. In the present invention, the whole blood separation membrane is preferably used as a sample pad of a test strip. The whole blood separation membrane, the reaction membrane and the water absorption pad are combined in a matching way to be used as a test strip; more preferably, the whole blood separation membrane, the reaction membrane and the water absorption pad are combined and placed in a plastic reagent shell to assemble a finished test strip; the finished test strip is preferably a rapid detection reagent based on the lateral chromatography immunofluorescence detection principle. In the invention, when the finished test strip is applied, preferably, a whole blood sample is added into a sample adding groove of a reagent shell, the waiting time is 15min, then the reagent shell is inserted into an analyzer, and the analyzer reads the concentration of a reactant to be detected in the whole blood sample. In the present invention, the specific reaction process of the detection is preferably as follows: the whole blood sample is contacted with one side of the whole blood separation membrane, and by absorption and separation of the whole blood separation membrane, a plasma portion containing a reactant (antigen) to be measured flows to the reaction membrane, a conjugate bound to the antigen is released onto the reaction membrane, a fluorescence signal value on the reaction membrane is detected by the analyzer, and the analyzer reads out the concentration of the reactant (antigen) to be measured in the whole blood sample through a preset and inputted standard curve. In the invention, the standard curve is prepared by the following method: the standard substance (such as troponin I antigen) of the object to be detected and a buffer solution (such as Tris) are mixed to prepare a standard solution with at least 5 concentrations from low to high, the standard solution is added to a reagent shell, an analyzer is used for detecting the fluorescence signal value of the standard solution, the concentration of the standard solution and the fluorescence signal value are compared (for example, set as an x axis and a y axis), a specific equation is fitted, and a standard curve is prepared.
The invention is not particularly limited with respect to the specific type of target detection substance, and preferably includes proteins, such as antigens, exemplified by troponin I in the practice of the invention.
The technical solutions provided by the present invention are described in detail below with reference to examples, but they should not be construed as limiting the scope of the present invention.
Example 1
Whole blood separation membrane for detecting troponin I
Whole blood separation membrane structure:
the reagents distributed from the top to the bottom of the separation membrane are respectively conjugate conjugates (4-6 mm from the top end), conjugate release reagents (4-6 mm from the top end), sealing reagents (15-25 mm from the top end) and hydrophilic reagents (4-6 mm from the bottom end).
The preparation method comprises the following steps:
1) mixing and incubating troponin I polyclonal antibody, immunoglobulin G, buffer solution (20mM MES) and microparticles with fluorescent labels for 60min to obtain conjugate solution;
2) mixing and coupling the conjugate solution, a blocking solution (2% sodium caseinate solution) and an EDAC solution (5mg/mL) for 2h to obtain an antigen-specific conjugate;
3) firstly, the prepared sealing reagent, the conjugate release reagent and the hydrophilic reagent are simultaneously distributed on a glass fiber membrane through a catheter, and after vacuum drying, the conjugate is distributed on the glass fiber membrane, and finally, the whole blood separation membrane is obtained through vacuum drying again. The vacuum degree of the vacuum drying is 8 Torr; the vacuum drying time is 3 h.
The application effect is as follows:
and (3) assembling a finished product reagent shell by using the whole blood separation membrane, reading the content of troponin I in a standard substance containing 1ng/mL of troponin I by combining an analyzer, comparing the detection result with the standard substance, and comparing the relative deviation of three detections with 10%, the intra-batch Coefficient of Variation (CV) with 18% and the inter-batch Coefficient of Variation (CV) with 20%. The linear correlation coefficient is more than or equal to 0.90, and the linear correlation coefficient is linear in the test range of 0.05ng/mL-30 ng/mL.
Specific detection data are as follows:
batch 1 assay data
Linearity
Taking 15 test boards, diluting the standard substance to 5 test samples with different concentrations in the measurement range, repeating the test on the same analyzer for 3 times, and obtaining the average value (y)i). In terms of sample concentration (x)i) As independent variable, to determine the mean value (y)i) As a dependent variable, the result should be linear with a linear correlation coefficient r of not less than 0.90.
The results are shown in Table 1.
TABLE 1 batch 1 Linear data
Substituting the measurement data into a formula:
calculated r is 0.9980.
Accuracy of
Taking 3 test boards, using sample solution with concentration of 0.4ng/mL as sample, using test board with same batch number, repeating measurement on the same analyzer for 3 times, and calculating average value
The relative deviation (B%) is calculated and should not be greater than 15%.
TABLE 2 accuracy data for batch 1
Substituting the average value and the marked value obtained by the calculation into a formula:
calculated B% ═ 4.17%.
Taking 20 test boards with high and low concentration, respectively testing with the same test board on the same analyzer, repeating the test for 10 times, and respectively calculating the average value of the test results
And the standard deviation (S), the relative standard deviation RSD (or coefficient of variation CV) should be no more than 20%.
(1) The high concentration assay data are shown in table 3.
TABLE 3 high concentration assay number
Calculating the mean of the measured values
Standard deviation SDHeight of＝0.82The mean and standard deviation are substituted into the formula:
calculated RSD (CV)Height of＝4.28。
(2) The low concentration assay data is shown in table 4.
TABLE 4 Low concentration assay data
Calculating the mean of the measured values
Standard deviation SDIs low inThe mean and standard deviation are substituted into the formula:
calculated RSD (CV)Is low in＝5.86％。
Batch 2 assay data
Linearity
Taking 15 test boards, diluting the standard substance to 5 test samples with different concentrations in the measurement range, repeating the test on the same analyzer for 3 times, and obtaining the average value (y)i). In terms of sample concentration (x)i) As independent variable, to determine the mean value (y)i) As a dependent variable, the result should be linear with a linear correlation coefficient r of not less than 0.90.
TABLE 5 batch 2 Linear data
Substituting the measurement data into a formula:
calculated r is 0.9988.
Accuracy of
Taking 3 test boards, using sample solution with concentration of 0.4ng/mL as sample, using test board with same batch number, repeating measurement on the same analyzer for 3 times, and calculating average value
The relative deviation (B%) is calculated and should not be greater than 15%.
Table 6 batch 2 accuracy data
Substituting the average value and the marked value obtained by the calculation into a formula:
calculated B% ═ 3.33%.
Precision in batch
Taking 20 test boards, using low (0.4ng/mL) and high (20.0ng/mL) quality control products as samples, using the test boards with the same batch number, respectively detecting on the same analyzer, repeatedly measuring each horizontal quality control product for 10 times, respectively calculating the average value of the detection results of each horizontal quality control product
And the standard deviation (S), the relative standard deviation RSD (or coefficient of variation CV) should be no more than 20%.
(2) The high concentration assay data are shown in Table 7.
TABLE 7 batch 2 high concentration assay data
Calculating the mean of the measured values
Standard deviation SDHeight of＝1.12The mean and standard deviation are substituted into the formula:
calculated RSD (CV)Height of＝5.89％。
(3) The low concentration assay data is shown in Table 8.
TABLE 8 batch 2 Low concentration assay data
Calculating the mean of the measured values
Standard deviation SDIs low in＝0.02The mean and standard deviation are substituted into the formula:
calculated RSD (CV)Is low in＝6.18％。
Batch 3 assay data
Linearity
Taking 15 test boards, diluting the standard substance to 5 test samples with different concentrations in the measurement range, repeating the test on the same analyzer for 3 times, and obtaining the average value (y)i). In terms of sample concentration (x)i) As independent variable, to determine the mean value (y)i) As a dependent variable, the result should be linear with a linear correlation coefficient r of not less than 0.90.
TABLE 9 batch 3 Linear data
Substituting the measurement data into a formula:
calculated r is 0.9994.
Accuracy of
Taking 3 test boards, using sample solution with concentration of 0.4ng/mL as sample, using test board with same batch number, repeating measurement on the same analyzer for 3 times, and calculating average value
The relative deviation (B%) is calculated and should not be greater than 15%.
TABLE 10 batch 3 accuracy data
Substituting the average value and the marked value obtained by the calculation into a formula:
calculated B% — 1.67%.
Precision in batch
Taking 20 test boards, using low and high concentration quality control materials as samples, using the same batch number test board, respectively detecting on the same analyzer, repeating the measurement for 10 times for each horizontal quality control material, and respectively calculating the average value of the detection results of each horizontal quality control material
And the standard deviation (S), the relative standard deviation RSD (or coefficient of variation CV) should be no more than 20%.
(3) The high concentration assay data is shown in Table 11.
TABLE 11 number of high assay with precision of batch 3
Calculating the mean of the measured values
Standard deviation SDHeight ofThe mean and standard deviation were substituted into the formula:
calculated RSD (CV)Height of＝6.17％。
(4) The low concentration assay data is shown in table 12.
TABLE 12 number of low assay with precision of batch 3
Calculating the mean of the measured values
Standard deviation SDIs low inThe mean and standard deviation are substituted into the formula:
calculated RSD (CV)Is low in＝5.12％。
3 batch to batch precision data
Batch precision 3 test panels were taken from three different batch number kits, each batch number, and the samples were analyzed on the same analyzer using a cTnI: 20ng/mL quality control product test, and respectively calculating the average value of the detection results of 3 batch number test boards
And calculating the total average value of the detection results of all three batches
Substituting the average value obtained by the calculation into a formula:
in (3), the relative range (R) between batches is calculated to be not more than 22%.
TABLE 133 batch-to-batch precision measurement data
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Claims (10)
1. A whole blood separation membrane for immunofluorescence chromatography detection is characterized in that a glass fiber membrane is used as a base material, and a conjugate with antigen specificity, a blocking reagent, a conjugate release reagent and a hydrophilic reagent are fixed on the glass fiber membrane;
the antigen-specific conjugate is composed of a polyclonal antibody specifically bound with a target detection object, immunoglobulin G and microparticles with fluorescent markers;
the conjugate is positioned at the top of the whole blood separation membrane and is 0.5-5 mm away from the top edge of the whole blood separation membrane;
the hydrophilic reagent is positioned at the bottom of the whole blood separation membrane and is 0.5-5 mm away from the bottom edge of the whole blood separation membrane;
the position of the conjugate releasing agent coincides with the position of the conjugate.
2. The whole blood separation membrane according to claim 1, wherein the blocking reagent is located in the middle of the whole blood separation membrane at a distance of 10-20 mm from the top edge of the whole blood separation membrane.
3. The whole blood separation membrane according to claim 1, wherein the blocking reagent comprises a first surfactant, a first blocking solution, a first buffer, sodium chloride, and a first preservative; the first surfactant comprises one or more of PVP10, S10G and Tween 20; the first sealing solution comprises one or more of a casein sodium salt solution, a bovine serum albumin solution and a heterogeneous sealing reagent HBR; the first preservative comprises ProClin300 or ProClin 950; the pH value of the sealing reagent is 7-9; the blocking reagent was dispensed in a volume of 10. mu.L/cm to full membrane saturation.
4. The whole blood separation membrane according to claim 1, wherein the conjugate releasing reagent includes a second surfactant, a second blocking solution, a second buffer, sodium chloride, and a second preservative; the second surfactant comprises PVP10 or S10G; the second sealing solution comprises a sodium caseinate solution; the second buffer comprises Tris; the second preservative ProClin300 or ProClin 950; the pH value of the conjugate release reagent is 7-9; the distribution volume of the conjugate release reagent is 10-50 muL/cm.
5. The whole blood separation membrane according to claim 1, wherein the hydrophilic agent includes a third surfactant, a third buffer, and a third preservative; the third surfactant is S10G; the third buffer solution is 20 mM-100mM Tris; the third corrosion inhibitor is ProClin300 or ProClin 950; the pH value of the hydrophilic reagent is 6.5-8.5; the distribution volume of the hydrophilic reagent is 10-50 mu L/cm.
6. The whole blood separation membrane according to claim 3 or 4, wherein the concentration of the first buffer solution and the concentration of the second buffer solution are independently 30 to 100 mM.
7. A method for preparing the whole blood separation membrane according to any one of claims 1 to 6, comprising the steps of:
1) mixing and incubating a polyclonal antibody specifically bound with a target detection object, immunoglobulin G, a buffer solution and microparticles with fluorescent labels for 15-60 min to obtain a conjugate solution;
2) mixing and coupling the conjugate solution, the sealing solution and the EDAC solution for 1-3 h to obtain an antigen-specific conjugate;
3) and fixing the antigen-specific conjugate, the blocking reagent, the conjugate releasing reagent and the hydrophilic reagent on a glass fiber membrane, and drying to obtain the whole blood separation membrane.
8. The method according to claim 7, wherein the drying in step 3) is vacuum drying, and the degree of vacuum of the vacuum drying is 3 to 15 Torr; and the vacuum drying time is 2-4 h.
9. Use of the whole blood separation membrane of any one of claims 1 to 6 in the preparation of a lateral flow immunofluorescence assay test strip.
10. The use of claim 9, wherein the whole blood separation membrane is used as a sample pad of a test strip.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011030495.4A CN114280312B (en) | 2020-09-27 | 2020-09-27 | Whole blood separation membrane for immunofluorescence chromatography detection and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011030495.4A CN114280312B (en) | 2020-09-27 | 2020-09-27 | Whole blood separation membrane for immunofluorescence chromatography detection and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114280312A true CN114280312A (en) | 2022-04-05 |
| CN114280312B CN114280312B (en) | 2023-09-15 |
Family
ID=80867519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011030495.4A Active CN114280312B (en) | 2020-09-27 | 2020-09-27 | Whole blood separation membrane for immunofluorescence chromatography detection and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114280312B (en) |
Citations (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2309528A1 (en) * | 1999-06-08 | 2000-12-08 | Ortho-Clinical Diagnostics, Inc. | Simultaneous determination of forward and reverse abo blood group |
| US20030049857A1 (en) * | 2001-06-07 | 2003-03-13 | Chan Hermes K.W. | Rapid diagnostic device, assay and multifunctional buffer |
| US6551842B1 (en) * | 1999-03-26 | 2003-04-22 | Idexx Laboratories, Inc. | Method and device for detecting analytes in fluids |
| WO2003102208A2 (en) * | 2002-05-31 | 2003-12-11 | Indian Council Of Agricultural Research | Rapid detection of bt-cry toxins |
| US20050214951A1 (en) * | 2002-01-23 | 2005-09-29 | Boditech Inc | Lateral flow quantitative assay method and strip and laser-induced fluoerescence detection device therefor |
| US20070148717A1 (en) * | 2002-04-10 | 2007-06-28 | Fong Whalley K | Sensitive immunochromatographic assay |
| KR100946566B1 (en) * | 2009-11-18 | 2010-03-11 | 주식회사 인포피아 | A lateral flow immunoassay device with a more rapid and accurate test result |
| WO2011012053A1 (en) * | 2009-07-31 | 2011-02-03 | 上海科新生物技术股份有限公司 | Test strip for detecting anti-cyclic citrullinated peptide antibody in blood and method of preparing the same |
| US20110076697A1 (en) * | 2009-04-28 | 2011-03-31 | Innovative Laboratory Technologies, Inc. | Lateral-flow immuno-chromatographic assay devices |
| CN102576007A (en) * | 2009-04-15 | 2012-07-11 | 瑞莱诊断体系股份有限公司 | Expanding the dynamic range of a test strip |
| JP2013181870A (en) * | 2012-03-02 | 2013-09-12 | Tanaka Kikinzoku Kogyo Kk | Test strip for immunochromatography |
| WO2015147291A1 (en) * | 2014-03-27 | 2015-10-01 | 田中貴金属工業株式会社 | Immunochromatographic analysis device and immunochromatographic analysis method |
| US20150293087A1 (en) * | 2012-09-28 | 2015-10-15 | Sekisui Medical Co., Ltd. | Additive for measuring diluted sample in non-dilution-type immunochromatographic method reagent |
| US20150316541A1 (en) * | 2013-01-16 | 2015-11-05 | Fujirebio Inc. | Method for immunologically assaying hemoglobin a1c in specimen |
| CN105424923A (en) * | 2015-09-10 | 2016-03-23 | 南京微测生物科技有限公司 | Color-fluorescence dual-function immunochromatography test strip and preparation method thereof |
| CN105699659A (en) * | 2016-01-29 | 2016-06-22 | 苏州联辰生物技术有限公司 | Tachysynthesis fluorescent quantitation detection kit for multi-index detection of myocardial infarction |
| CN106248958A (en) * | 2016-07-21 | 2016-12-21 | 上海奥普生物医药有限公司 | The fluorescence immune chromatography reagent of a kind of detection by quantitative cTnI and preparation method |
| US20170045510A1 (en) * | 2014-04-25 | 2017-02-16 | Tanaka Kikinzoku Kogyo K.K. | Immunochromatographic analysis device, immunochromatographic analysis method, and immunochromatographic analysis kit |
| CN106645043A (en) * | 2015-10-30 | 2017-05-10 | 上海市刑事科学技术研究院 | Kit and method for fast quantitatively detecting small molecule compound |
| US20170219608A1 (en) * | 2014-05-22 | 2017-08-03 | Wenbo HU | Kit for rapidly testing myocardial infarction and a preparation method and an application thereof |
| CN107144693A (en) * | 2017-05-02 | 2017-09-08 | 暨南大学 | Detect CD4 in blood+Lateral chromatography kit of T cell quantity and preparation method thereof |
| CN107430120A (en) * | 2015-08-17 | 2017-12-01 | 积水医疗株式会社 | Immunologic detection method and the test-strips for it |
| CN107449898A (en) * | 2017-07-11 | 2017-12-08 | 中检国研(北京)科技有限公司 | A kind of yapamicin relict fluorescence immune chromatography test paper and preparation method thereof |
| JP2018040797A (en) * | 2016-09-05 | 2018-03-15 | 株式会社ファンケル | Examination kit for ferritin detection, and ferritin detecting method |
| WO2018120856A1 (en) * | 2016-12-28 | 2018-07-05 | 广州瑞博奥生物科技有限公司 | Time-resolved fluorescent immunochromatographic test strip and kit for detecting ctni, and preparation method therefor |
| WO2018167261A1 (en) * | 2017-03-17 | 2018-09-20 | Porcher Industries | Device and method for rapid testing of a liquid sample |
| JP6426872B1 (en) * | 2018-08-02 | 2018-11-21 | 積水メディカル株式会社 | Immunochromatographic test strip and immunochromatographic detection kit |
| CN109187975A (en) * | 2018-08-08 | 2019-01-11 | 施康培医疗科技（武汉）有限公司 | A kind of medullary carcinoma of thyroid gland joint-detection colloidal gold immuno-chromatography test paper strip |
| CN109324181A (en) * | 2018-10-22 | 2019-02-12 | 河北特温特生物科技发展有限公司 | A kind of preparation method of immunochromatography sealant compositions, purposes and immune chromatography reagent kit |
| CN109521207A (en) * | 2018-12-28 | 2019-03-26 | 广州菲康生物技术有限公司 | A kind of IGF-1 fluorescence immune chromatography detection kit |
| CN109613256A (en) * | 2018-11-21 | 2019-04-12 | 杭州康知生物科技有限公司 | It urinates four kinds of traces of albumin and quantifies joint inspection fluorescence immune chromatography kit and preparation method |
| CN109725154A (en) * | 2018-10-08 | 2019-05-07 | 杭州康知生物科技有限公司 | A kind of IgG4 fluorescence immune chromatography assay kit and measuring method |
| CN209102726U (en) * | 2018-10-22 | 2019-07-12 | 河北特温特生物科技发展有限公司 | Placenta growth factor fluorescence immune chromatography test paper bar, test board and kit |
| CN110376386A (en) * | 2019-07-26 | 2019-10-25 | 北京丹大生物技术有限公司 | A kind of preparation method detecting the test strips of mycophenolic acid, kit and test strips |
| CN110441538A (en) * | 2019-08-23 | 2019-11-12 | 北京丹大生物技术有限公司 | A kind of immuno-chromatographic test paper strip and its application for detecting digoxin |
| JP2020052028A (en) * | 2019-01-07 | 2020-04-02 | 積水メディカル株式会社 | Immunochromatography test piece |
| WO2020067233A1 (en) * | 2018-09-27 | 2020-04-02 | 積水メディカル株式会社 | Test piece for immunochromatography |
| JP2020052017A (en) * | 2018-09-28 | 2020-04-02 | 日鉄ケミカル＆マテリアル株式会社 | Sample treatment solution and immunochromatography kit using the same |
| WO2020105079A1 (en) * | 2018-11-19 | 2020-05-28 | 積水メディカル株式会社 | Test piece for immunochromatography and immunochromatographic detection kit |
| US20200399672A1 (en) * | 2018-02-09 | 2020-12-24 | Osaka University | Immunochromatographic analysis device for chikungunya virus detection |
-
2020
- 2020-09-27 CN CN202011030495.4A patent/CN114280312B/en active Active
Patent Citations (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6551842B1 (en) * | 1999-03-26 | 2003-04-22 | Idexx Laboratories, Inc. | Method and device for detecting analytes in fluids |
| CA2309528A1 (en) * | 1999-06-08 | 2000-12-08 | Ortho-Clinical Diagnostics, Inc. | Simultaneous determination of forward and reverse abo blood group |
| US20030049857A1 (en) * | 2001-06-07 | 2003-03-13 | Chan Hermes K.W. | Rapid diagnostic device, assay and multifunctional buffer |
| US20050214951A1 (en) * | 2002-01-23 | 2005-09-29 | Boditech Inc | Lateral flow quantitative assay method and strip and laser-induced fluoerescence detection device therefor |
| US20070148717A1 (en) * | 2002-04-10 | 2007-06-28 | Fong Whalley K | Sensitive immunochromatographic assay |
| WO2003102208A2 (en) * | 2002-05-31 | 2003-12-11 | Indian Council Of Agricultural Research | Rapid detection of bt-cry toxins |
| CN102576007A (en) * | 2009-04-15 | 2012-07-11 | 瑞莱诊断体系股份有限公司 | Expanding the dynamic range of a test strip |
| US20110076697A1 (en) * | 2009-04-28 | 2011-03-31 | Innovative Laboratory Technologies, Inc. | Lateral-flow immuno-chromatographic assay devices |
| WO2011012053A1 (en) * | 2009-07-31 | 2011-02-03 | 上海科新生物技术股份有限公司 | Test strip for detecting anti-cyclic citrullinated peptide antibody in blood and method of preparing the same |
| KR100946566B1 (en) * | 2009-11-18 | 2010-03-11 | 주식회사 인포피아 | A lateral flow immunoassay device with a more rapid and accurate test result |
| JP2013181870A (en) * | 2012-03-02 | 2013-09-12 | Tanaka Kikinzoku Kogyo Kk | Test strip for immunochromatography |
| US20150293087A1 (en) * | 2012-09-28 | 2015-10-15 | Sekisui Medical Co., Ltd. | Additive for measuring diluted sample in non-dilution-type immunochromatographic method reagent |
| US20150316541A1 (en) * | 2013-01-16 | 2015-11-05 | Fujirebio Inc. | Method for immunologically assaying hemoglobin a1c in specimen |
| WO2015147291A1 (en) * | 2014-03-27 | 2015-10-01 | 田中貴金属工業株式会社 | Immunochromatographic analysis device and immunochromatographic analysis method |
| US20170045510A1 (en) * | 2014-04-25 | 2017-02-16 | Tanaka Kikinzoku Kogyo K.K. | Immunochromatographic analysis device, immunochromatographic analysis method, and immunochromatographic analysis kit |
| US20170219608A1 (en) * | 2014-05-22 | 2017-08-03 | Wenbo HU | Kit for rapidly testing myocardial infarction and a preparation method and an application thereof |
| CN107430120A (en) * | 2015-08-17 | 2017-12-01 | 积水医疗株式会社 | Immunologic detection method and the test-strips for it |
| CN105424923A (en) * | 2015-09-10 | 2016-03-23 | 南京微测生物科技有限公司 | Color-fluorescence dual-function immunochromatography test strip and preparation method thereof |
| CN106645043A (en) * | 2015-10-30 | 2017-05-10 | 上海市刑事科学技术研究院 | Kit and method for fast quantitatively detecting small molecule compound |
| CN105699659A (en) * | 2016-01-29 | 2016-06-22 | 苏州联辰生物技术有限公司 | Tachysynthesis fluorescent quantitation detection kit for multi-index detection of myocardial infarction |
| CN106248958A (en) * | 2016-07-21 | 2016-12-21 | 上海奥普生物医药有限公司 | The fluorescence immune chromatography reagent of a kind of detection by quantitative cTnI and preparation method |
| JP2018040797A (en) * | 2016-09-05 | 2018-03-15 | 株式会社ファンケル | Examination kit for ferritin detection, and ferritin detecting method |
| WO2018120856A1 (en) * | 2016-12-28 | 2018-07-05 | 广州瑞博奥生物科技有限公司 | Time-resolved fluorescent immunochromatographic test strip and kit for detecting ctni, and preparation method therefor |
| WO2018167261A1 (en) * | 2017-03-17 | 2018-09-20 | Porcher Industries | Device and method for rapid testing of a liquid sample |
| CN107144693A (en) * | 2017-05-02 | 2017-09-08 | 暨南大学 | Detect CD4 in blood+Lateral chromatography kit of T cell quantity and preparation method thereof |
| CN107449898A (en) * | 2017-07-11 | 2017-12-08 | 中检国研(北京)科技有限公司 | A kind of yapamicin relict fluorescence immune chromatography test paper and preparation method thereof |
| US20200399672A1 (en) * | 2018-02-09 | 2020-12-24 | Osaka University | Immunochromatographic analysis device for chikungunya virus detection |
| JP6426872B1 (en) * | 2018-08-02 | 2018-11-21 | 積水メディカル株式会社 | Immunochromatographic test strip and immunochromatographic detection kit |
| CN109187975A (en) * | 2018-08-08 | 2019-01-11 | 施康培医疗科技（武汉）有限公司 | A kind of medullary carcinoma of thyroid gland joint-detection colloidal gold immuno-chromatography test paper strip |
| WO2020067233A1 (en) * | 2018-09-27 | 2020-04-02 | 積水メディカル株式会社 | Test piece for immunochromatography |
| JP2020052017A (en) * | 2018-09-28 | 2020-04-02 | 日鉄ケミカル＆マテリアル株式会社 | Sample treatment solution and immunochromatography kit using the same |
| CN109725154A (en) * | 2018-10-08 | 2019-05-07 | 杭州康知生物科技有限公司 | A kind of IgG4 fluorescence immune chromatography assay kit and measuring method |
| CN109324181A (en) * | 2018-10-22 | 2019-02-12 | 河北特温特生物科技发展有限公司 | A kind of preparation method of immunochromatography sealant compositions, purposes and immune chromatography reagent kit |
| CN209102726U (en) * | 2018-10-22 | 2019-07-12 | 河北特温特生物科技发展有限公司 | Placenta growth factor fluorescence immune chromatography test paper bar, test board and kit |
| WO2020105079A1 (en) * | 2018-11-19 | 2020-05-28 | 積水メディカル株式会社 | Test piece for immunochromatography and immunochromatographic detection kit |
| CN109613256A (en) * | 2018-11-21 | 2019-04-12 | 杭州康知生物科技有限公司 | It urinates four kinds of traces of albumin and quantifies joint inspection fluorescence immune chromatography kit and preparation method |
| CN109521207A (en) * | 2018-12-28 | 2019-03-26 | 广州菲康生物技术有限公司 | A kind of IGF-1 fluorescence immune chromatography detection kit |
| JP2020052028A (en) * | 2019-01-07 | 2020-04-02 | 積水メディカル株式会社 | Immunochromatography test piece |
| CN110376386A (en) * | 2019-07-26 | 2019-10-25 | 北京丹大生物技术有限公司 | A kind of preparation method detecting the test strips of mycophenolic acid, kit and test strips |
| CN110441538A (en) * | 2019-08-23 | 2019-11-12 | 北京丹大生物技术有限公司 | A kind of immuno-chromatographic test paper strip and its application for detecting digoxin |
Non-Patent Citations (13)
Also Published As
| Publication number | Publication date |
|---|---|
| CN114280312B (en) | 2023-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11391746B2 (en) | Testing device for identifying antigens and antibodies in biofluids | |
| EP2623982B1 (en) | Test strip for immunochromatography, and process for production thereof | |
| DK160108C (en) | Method and equipment for direct or indirect detection of reaction between a specific binding agent and the corresponding acceptor substance | |
| CA1236011A (en) | Assay method for whole blood samples | |
| JP5181058B2 (en) | Method and kit for rapidly determining human ABO / RH / MN blood type | |
| EP1047943B1 (en) | Chromatographic assay device and method for detecting the presence of an analyte in a blood sample | |
| JP4216838B2 (en) | Non-continuous immunoassay device and immunoassay method using the same | |
| CN111413506A (en) | Application of detection test strip in preparation of kit for detecting P L A2R antibody | |
| JP7352831B2 (en) | Immunochromatography test piece, measurement kit, and measurement method | |
| EP3486654B1 (en) | Detection method using immunochromatography | |
| EP2042868A1 (en) | Immunochromatographic test device | |
| AU592971B2 (en) | Solid phase diffusion assay | |
| EP2290367A1 (en) | Method for detecting objective substance and kit for detecting objective substance | |
| EP0746767B1 (en) | Analyzer cuvette, method and diagnostic test kit for determination of analytes in whole blood samples | |
| CN111983229A (en) | Reagent strip for quantitatively detecting helicobacter pylori antibody by colloidal gold and detection method | |
| EP4249508A1 (en) | Sars-cov-2 detection kit and sars-cov-2 detection method | |
| CN112034170A (en) | Reagent card for quantitatively detecting helicobacter pylori antibody by fluorescence chromatography and detection method | |
| CN113804887A (en) | Immunoassay kit with multiple detection scales and application thereof | |
| JPH11133023A (en) | Compound for reducing influence of urea on chromatographic immunoassay using urine sample | |
| CN116027035B (en) | Kit for improving detection accuracy of HIV1/2 urine colloidal gold immunochromatography and preparation method thereof | |
| JP2553852B2 (en) | Immunological assay for biological substances in samples | |
| JPS63210664A (en) | Dry test piece for device using oxygen demand detection system and detecting method of analytic component in fluid to be inspected | |
| CN114280312B (en) | Whole blood separation membrane for immunofluorescence chromatography detection and preparation method and application thereof | |
| JPS63501819A (en) | Immunoassay methods and kits | |
| CN111487407A (en) | Detection kit for S100B protein and use method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |